Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå ¿¹Ãø - Áö¿ªº° ºÐ¼® : Àå±â À¯Çüº°, ¿ëµµº°, °ø±Þ¿øº°, À¯Çüº°(-2030³â)
South & Central America Organoids Market Forecast to 2030 - Regional Analysis - by Organ Type, Application, Source, and Type
»óǰÄÚµå : 1420138
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2023³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 82 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,450 £Ü 4,937,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 4,450 £Ü 6,368,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,450 £Ü 7,800,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀåÀº 2022³â 1¾ï 3,238¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2030³â¿¡´Â 6¾ï 5,425¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 2022³âºÎÅÍ 2030³â±îÁö CAGRÀº 22.1%·Î ÃßÁ¤µË´Ï´Ù.

â¾à Ȱµ¿¿¡ ´ëÇÑ ÁÖ·ÂÀÌ Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀåÀ» µÞ¹Þħ

½Å¾à ¹× ÷´Ü¾à¿¡ ´ëÇÑ ¼ö¿äÀÇ °íÁ¶°¡, â¾à ¹× ¿¬±¸ ÀüüÀÇ ÆäÀ̽º¸¦ ¹Ð¾î ¿Ã¸®°í ÀÖ½À´Ï´Ù. ClinicalTrials.gov¿¡ µû¸£¸é 2020³â ÃÑ ÀÓ»ó½ÃÇè ¼ö´Â 356,282°ÇÀ¸·Î ÃßÁ¤µË´Ï´Ù. Hubrecht ¿¬±¸¼ÒÀÇ ÃÖ±Ù Á¶»ç¿¡ µû¸£¸é, ¿À°¡³ëÀ̵å´Â ±× ¾à¹°ÀÇ ÇýÅÃÀ» ¹ÞÀ» ¼ö ¾ø´Â ȯÀÚ¸¦ È®ÀÎÇÔÀ¸·Î½á °ªºñ½Ñ ¾à¹°ÀÇ ºñ¿ë È¿°ú¸¦ ³ôÀÏ ¼ö ÀÖ´Ù°í ÇÕ´Ï´Ù. ¼¼°èÀÇ ÀÓ»ó½ÃÇè Áõ°¡´Â ¿À°¡³ëÀÌµå ¸ðµ¨À» Æ÷ÇÔÇÑ Ã·´Ü ÀÇ·á±â¼ú ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°Ô´Ù°¡, â¾à¿¡ À־ÀÇ ¿À°¡³ëÀ̵å´Â ¾Ï¿¡¸¸ ÇÑÁ¤µÇÁö ¾Ê°í, ³¶Æ÷¼º ¼¶À¯Áõ, ´Ù¹ß¼º ³¶Æ÷½Å, ¼ÒµÎÁõ, ÀåÀ̳ª ±âµµÀÇ °¨¿°Áõ µî, ´Ù¸¥ Áúȯ¿¡µµ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¿À°¡³ëÀ̵å´Â ±â°üÀÇ ±¸Á¶ ¹× ±â´É°ú °°Àº ±â°üÀÇ Æ¯¼ºÀ» ¿ä¾àÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿À°¡³ëÀ̵å´Â Á¶Á÷À̳ª Àå±âÀÇ º»·¡ÀÇ À¯ÀüÀû ¹× ÈļºÀû »óŸ¦ º¹¿øÇÒ ¼ö Àֱ⠶§¹®¿¡ À¯ÀüÀÚ ÆíÁý¿¡ ÀûÇÕÇÕ´Ï´Ù. ´Ù¾çÇÑ ¿¬±¸´Â CRISPR-Cas9 ±â¼ú°ú ¿À°¡³ëÀ̵åÀÇ Á¶ÇÕ¿¡ ÀÇÇÑ ÁÁÀº °á°ú¸¦ º¸¿©ÁÖ¸ç, ³¶Æ÷¼º ¼¶À¯Áõ¿¡¼­ ȹ±âÀûÀÎ ±âȸ¸¦ ³ÐÈ÷°í ÀÖ½À´Ï´Ù. 2020³â¿¡ ¹ßÇ¥µÈ ¿¬±¸ 'CRISPR-Based Adenine Editors Correct Nonsense Mutation in a Cystic Fibrosis Organoid Biobank'¿¡ µû¸£¸é, ³¶Æ÷¼º ¼¶À¯Áõ Àå°ü ¿À°¡³ëÀ̵åÀÇ ¹ÙÀÌ¿À¹ðÅ©´Â 664¸íÀÇ È¯ÀÚ¸¦ ´ëÇ¥Çϰí, ±× Áß 20%±îÁö ¾Æµ¥´Ñ ¿°±â ÆíÁý±â´Â ³¶Æ÷¼º ¼¶À¯Áõ ¸· °üÅë ÀüµµÃ¼ ¼ö¿ëüÀÇ ³­¼¾½º µ¹¿¬º¯À̸¦ ÀÌ·ÐÀûÀ¸·Î È¿À²ÀûÀ¸·Î º¹±¸ÇÒ ¼ö ÀÖ¾ú½À´Ï´Ù. ÀϺΠµ¿¹° ¸ðµ¨¿¡¼­ À¯ÀüÀÚ ÆíÁý ¿À°¡³ëÀ̵åÀÇ ¼º°ú´Â ÀÖÁö¸¸, ±× È¿À²Àº ÇöÀúÈ÷ ³·°í ¼º°ø·üÀº ³ôÁö ¾Ê½À´Ï´Ù. ±×·¯¹Ç·Î À¯ÀüÀÚ ÆíÁý ¿À°¡³ëÀ̵åÀÇ ¾ÈÀü¼º, Àå±â ¾ÈÁ¤¼º ¹× ±â´É¼ºÀ» À§ÇÑ °úÁ¤ÀÇ ¿¬±¸ °³¹ßÀº ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

¶ÇÇÑ COVID-19ÀÇ À¯ÇàÀº Àΰ£ÀÇ Æó À¯±âü ¸ðµ¨À» °³¹ßÇÒ Çʿ伺À» ÀÏÀ¸Ä×½À´Ï´Ù. ¿¹¸¦ µé¾î, Millipore Sigma´Â 3dGRO Àΰ£ Æó ¿À°¡³ëÀÌµå ¹è¾ç ½Ã½ºÅÛÀ» °³¹ßÇß½À´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº ¿¬±¸ÀÚ°¡ Àΰ£ Æó »óÇÇÀÇ ¿À°¡³ëÀÌµå ¸ðµ¨À» ¹è¾çÇϱâ À§ÇÑ Àå±â Á¶Á÷À» Á¦¾îÇϰí, Á¢±ÙÇϰí, ÀçÇöÇÒ ¼ö ÀÖ°Ô Çϰí, ¿¬±¸ Áß¿¡ ±àÁ¤ÀûÀÌ°í ¼º°øÀûÀÎ °á°ú¸¦ ¾ò´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ Çõ½ÅÀº ½ÃÀå ¼ºÀå¿¡ ´õ Å« ¼ºÀå ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå °³¿ä

Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀåÀº ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª ¹× ±âŸ Áß³²¹Ì·Î ±¸ºÐµË´Ï´Ù. ÀÌ Áö¿ª ½ÃÀåÀº ¾Ï ȯÀÚ Áõ°¡, Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡, ¿À°¡³ëÀ̵åÀÇ ¿¬±¸°³¹ß Áõ°¡¿¡ ÀÇÇØ ¼ºÀåÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå ¼öÀÍ ¹× ¿¹Ãø(±Ý¾×)(-2030³â)

Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå ¼¼ºÐÈ­

Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀåÀº Àå±â À¯Çüº°, ¿ëµµº°, °ø±Þ¿øº°, ±¹°¡º°·Î ±¸ºÐµË´Ï´Ù.

Àå±â À¯Çü¿¡ µû¶ó Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀåÀº Àå, °£, À§, ÃéÀå, Æó, ³ú, ½ÅÀå µîÀ¸·Î ±¸ºÐµË´Ï´Ù. Àå ºÎ¹®Àº 2022³â Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

À¯Çüº°·Î º¸¸é Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀåÀº ±â±¸, ¼Ò¸ðǰ, ¼­ºñ½º·Î ±¸ºÐµË´Ï´Ù. ¼Ò¸ðǰ ºÎ¹®Àº 2022³â Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

¿ëµµº°·Î´Â Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀåÀº ¹ß»ý »ý¹°ÇÐ Áúȯ, °¨¿°Áõ º´¸®ÇÐ, Àç»ý ÀÇ·á, ¾à¹° µ¶¼º ¹× À¯È¿¼º ½ÃÇè, â¾à ¹× ¸ÂÃãÇü ÀÇ·á, ±âŸ·Î ±¸ºÐµË´Ï´Ù. 2022³â Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå¿¡¼­´Â ¹ß»ý »ý¹°ÇÐ Áúȯ ºÐ¾ß°¡ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

Ãâó¸¦ ±â¹ÝÀ¸·Î Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀåÀº ´Ù´É¼º Áٱ⠼¼Æ÷¿Í Àå±â ƯÀÌÀûÀÎ ¼ºÃ¼ Áٱ⠼¼Æ÷·Î À̺е˴ϴÙ. 2022³â Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå¿¡¼­´Â ´Ù´É¼º Áٱ⼼Æ÷ ºÐ¾ß°¡ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

±¹°¡º°·Î º¸¸é Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀåÀº ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª, ±âŸ Áß³²¹Ì·Î ±¸ºÐµË´Ï´Ù. 2022³â Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀåÀº ºê¶óÁúÀÌ µ¶Á¡Çß½À´Ï´Ù.

Cellsce, InSphero, Merck KGaA, STEMCELL Technologies Inc, Thermo Fisher Scientific Inc´Â Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå »óȲ

Á¦5Àå Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå : ÁÖ¿ä »ê¾÷ ¿ªÇÐ

Á¦6Àå ¿À°¡³ëÀÌµå ½ÃÀå : Áß³²¹Ì ½ÃÀå ºÐ¼®

Á¦7Àå Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå-¼öÀÍ ¹× ¿¹Ãø : Àå±â À¯Çüº°(-2030³â)

Á¦8Àå Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå-¼öÀÍ ¹× ¿¹Ãø : ¿ëµµº°(-2030³â)

Á¦9Àå Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå-¼öÀÍ ¹× ¿¹Ãø : °ø±Þ¿øº°(-2030³â)

Á¦10Àå Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå-¼öÀÍ ¹× ¿¹Ãø : À¯Çüº°(-2030³â)

Á¦11Àå Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå : ±¹°¡º° ºÐ¼®

Á¦12Àå COVID-19 ÀüÈÄÀÇ ¿µÇâ

Á¦13Àå Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå ¾÷°è Á¤¼¼

Á¦14Àå Áß³²¹ÌÀÇ ¿À°¡³ëÀÌµå ½ÃÀå-ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦15Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The South & Central America organoids market is expected to grow from US$ 132.38 million in 2022 to US$ 654.25 million by 2030. It is estimated to grow at a CAGR of 22.1% from 2022 to 2030.

Focus on Drug Discovery Activities Fuel South & Central America Organoids Market

The increasing demand for new and advanced drugs is driving the overall pace of drug discovery and research. According to ClinicalTrials.gov, the total number of clinical trial studies in 2020 was estimated to be 356,282. A recent survey by the Hubrecht Institute states that organoids can potentially make expensive drugs more cost-effective by identifying patients who are not likely to benefit from the drug. An increasing number of clinical trials worldwide is expected to drive the demand for advanced medical technologies, including organoid models.

Further, organoids in drug discovery are not limited to just cancer, they are also used in other diseases, such as cystic fibrosis, polycystic kidney disease, microcephaly, and infectious diseases of the gut and airway. For instance, organoids can summarize the properties of an organ, such as organ structure and function. Also, organoids can restore a tissue or organ's original genetic and epigenetic state, making them suitable for gene editing. Various studies have shown positive results of combining CRISPR-Cas9 technology with organoids, which has expanded opportunities for breakthroughs in cystic fibrosis. According to a study 'CRISPR-Based Adenine Editors Correct Nonsense Mutations in a Cystic Fibrosis Organoid Biobank,' published in 2020, a biobank of cystic fibrosis intestinal organoids represented 664 patients, and ~20% of them were theoretically able to efficiently repair nonsense mutations in the cystic fibrosis transmembrane conductor receptor through adenine base editors. Despite a few achievements of gene-edited organoids in some animal models, their efficiency is significantly low, and the success rate is not high. Therefore, it is crucial to research and develop a process for gene-edited organoids' safety, long-term stability, and functionality.

Moreover, the COVID-19 pandemic triggered the need to develop human lung organoid models. For instance, MilliporeSigma developed a 3dGRO Human Lung Organoid Culture System that allows researchers to control, access, and reproduce organ tissue for culturing an organoid model of human lung epithelium that can aid in obtaining positive and successful results during their research. Thus, such innovations are expected to offer more significant growth opportunities for the market growth.

South & Central America Organoids Market Overview

The South & Central America organoids market is segmented into Brazil, Argentina, and the Rest of South & Central America. The market in the region is expected to grow due to the increasing number of cancer cases, growing government initiatives, and rising research and development for organoids.

South & Central America Organoids Market Revenue and Forecast to 2030 (US$ Million)

South & Central America Organoids Market Segmentation

The South & Central America organoids market is segmented into organ type, type, application, Source, and country.

Based on organ type, the South & Central America organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held the largest share of the South & Central America organoids market in 2022.

Based on type, the South & Central America organoid market is segmented into instruments, consumables, and services. The consumables segment held the largest share of the North America organoid market in 2022.

Based on application, the South & Central America organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held largest share of the South & Central America organoids market in 2022.

Based on source, the South & Central America organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held the larger share of the South & Central America organoids market in 2022.

Based on country, the South & Central America organoids market is segmented into the Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America organoids market in 2022.

Cellesce, InSphero, Merck KGaA, STEMCELL Technologies Inc, and Thermo Fisher Scientific Inc, are some of the leading companies operating in the South & Central America organoids market.

Reasons to Buy:

Table Of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. South & Central America Organoids Market Landscape

5. South & Central America Organoids Market - Key Industry Dynamics

6. Organoids Market - South & Central America Market Analysis

7. South & Central America Organoids Market - Revenue and Forecast to 2030 - by Organ Type.

8. South & Central America Organoids Market - Revenue and Forecast to 2030 - by Application.

9. South & Central America Organoids Market - Revenue and Forecast to 2030 - by Source.

10. South & Central America Organoids Market - Revenue and Forecast to 2030 - by Type

11. South & Central America Organoids Market - Country Analysis

12. Pre & Post COVID-19 Impact

13. South & Central America Organoids Market Industry Landscape

14. South & Central America Organoids Market, Key Company Profiles

15. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â